These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 27282480)

  • 1. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
    Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
    Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
    Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
    Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering the mechanisms of selective inhibition for the tandem BD1/BD2 in the BET-bromodomain family.
    Cheng C; Diao H; Zhang F; Wang Y; Wang K; Wu R
    Phys Chem Chem Phys; 2017 Sep; 19(35):23934-23941. PubMed ID: 28849824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
    Picaud S; Wells C; Felletar I; Brotherton D; Martin S; Savitsky P; Diez-Dacal B; Philpott M; Bountra C; Lingard H; Fedorov O; Müller S; Brennan PE; Knapp S; Filippakopoulos P
    Proc Natl Acad Sci U S A; 2013 Dec; 110(49):19754-9. PubMed ID: 24248379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
    Jahagirdar R; Attwell S; Marusic S; Bendele A; Shenoy N; McLure KG; Gilham D; Norek K; Hansen HC; Yu R; Tobin J; Wagner GS; Young PR; Wong NCW; Kulikowski E
    Mol Pharmacol; 2017 Dec; 92(6):694-706. PubMed ID: 28974538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails.
    Huang H; Zhang J; Shen W; Wang X; Wu J; Wu J; Shi Y
    BMC Struct Biol; 2007 Sep; 7():57. PubMed ID: 17848202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4.
    Wang Q; Li Y; Xu J; Wang Y; Shi D; Liu L; Leung EL; Yao X
    Proteins; 2019 Jan; 87(1):3-11. PubMed ID: 30260047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution.
    Vollmuth F; Blankenfeldt W; Geyer M
    J Biol Chem; 2009 Dec; 284(52):36547-36556. PubMed ID: 19828451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of
    Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
    J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors.
    Ma J; Chen H; Yang J; Yu Z; Huang P; Yang H; Zheng B; Liu R; Li Q; Hu G; Chen Z
    Bioorg Med Chem; 2019 May; 27(9):1871-1881. PubMed ID: 30926312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors.
    Bharatham N; Slavish PJ; Shadrick WR; Young BM; Shelat AA
    J Mol Graph Model; 2018 May; 81():197-210. PubMed ID: 29605436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural investigation of a pyrano-1,3-oxazine derivative and the phenanthridinone core moiety against BRD2 bromodomains.
    Arole AH; Deshmukh P; Sridhar A; Padmanabhan B
    Acta Crystallogr F Struct Biol Commun; 2022 Mar; 78(Pt 3):119-127. PubMed ID: 35234137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
    McLure KG; Gesner EM; Tsujikawa L; Kharenko OA; Attwell S; Campeau E; Wasiak S; Stein A; White A; Fontano E; Suto RK; Wong NC; Wagner GS; Hansen HC; Young PR
    PLoS One; 2013; 8(12):e83190. PubMed ID: 24391744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.
    Shadrick WR; Slavish PJ; Chai SC; Waddell B; Connelly M; Low JA; Tallant C; Young BM; Bharatham N; Knapp S; Boyd VA; Morfouace M; Roussel MF; Chen T; Lee RE; Kiplin Guy R; Shelat AA; Potter PM
    Bioorg Med Chem; 2018 Jan; 26(1):25-36. PubMed ID: 29170024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
    Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
    ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
    Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
    J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.